In this podcast, Motley Fool analyst Karl Thiel joins host Ricky Mulvey to check in on the GLP-1 landscape. They discuss: How ...

Novo’s share price fell 8 per cent on Monday, having previously dived in December after a late-stage trial of CagriSema in overweight or obese people without diabetes found they lost an average of ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...

The late TV doctor’s wife Dr Clare Bailey Mosley is also bringing out a cookbook titled Eating Together: A Recipe For ...

From the likes of Kathy Bates and Sharon Osbourne to Whoopi Goldberg and Oprah Winfrey, there are a number of stars who have ...

New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

CagriSema, which is a combination of cagrilintide 2.4-milligram and semaglutide 2.4-mg doses, is being developed so people have a better choice for a weight-loss drug when the patents on Ozempic and ...

A RETROSPECTIVE study conducted by Mass General Brigham researchers has found that taking semaglutide before bariatric ...

Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a ...

Glp-1s cover a variety of drugs that are commonly used for weight loss, such as Ozempic, Wegovy and Mounjaro. And West Virginians used them at the highest rate ...

The increasing popularity of weight loss drugs like Wegovy, Ozempic, Mounjaro and metformin may have you wondering how all ...